EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hippocampal aggregation signatures of pathogenic UBQLN2 in amyotrophic lateral sclerosis and frontotemporal dementia

Kyrah M Thumbadoo, Birger V Dieriks, Helen C Murray iD, Molly E V Swanson iD, Ji Hun Yoo, Nasim F Mehrabi, Clinton Turner iD, Michael Dragunow, Richard L M Faull, Maurice A Curtis, Teepu Siddique, Christopher E Shaw und 5 weitere

Brain · 2024

DOI: 10.1093/brain/awae140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2024. Verfasst von Kyrah M Thumbadoo und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, University of Auckland, Auckland 1010, New Zealand. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Autophagy-Related Proteins, Hippocampus. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amelia Pais-Rodriguez and Marcus Gerbich, Michael J Fox Foundation, Health Research Council Sir Charles Hercus Health Research Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathogenic variants in the UBQLN2 gene cause X-linked dominant amyotrophic lateral sclerosis and/or frontotemporal dementia characterized by ubiquilin 2 aggregates in neurons of the motor cortex, hippocampus and spinal cord. However, ubiquilin 2 neuropathology is also seen in sporadic and familial amyotrophic lateral sclerosis and/or frontotemporal dementia cases not caused by UBQLN2 pathogenic variants, particularly C9orf72-linked cases. This makes the mechanistic role of mutant ubiquilin 2 protein and the value of ubiquilin 2 pathology for predicting genotype unclear. Here we examine a cohort of 44 genotypically diverse amyotrophic lateral sclerosis cases with or without frontotemporal dementia, including eight cases with UBQLN2 variants [resulting in p.S222G, p.P497H, p.P506S, p.T487I (two cases) and p.P497L (three cases)]. Using multiplexed (five-label) fluorescent immunohistochemistry, we mapped the co-localization of ubiquilin 2 with phosphorylated TDP-43, dipeptide repeat aggregates and p62 in the hippocampus of controls (n = 6), or amyotrophic lateral sclerosis with or without frontotemporal dementia in sporadic (n = 20), unknown familial (n = 3), SOD1-linked (n = 1), FUS-linked (n = 1), C9orf72-linked (n = 5) and UBQLN2-linked (n = 8) cases. We differentiate between (i) ubiquilin 2 aggregation together with phosphorylated TDP-43 or dipeptide repeat proteins; and (ii) ubiquilin 2 self-aggregation promoted by UBQLN2 pathogenic variants that cause amyotrophic lateral sclerosis and/or frontotemporal dementia. Overall, we describe a hippocampal protein aggregation signature that fully distinguishes mutant from wild-type ubiquilin 2 in amyotrophic lateral sclerosis with or without frontotemporal dementia, whereby mutant ubiquilin 2 is more prone than wild-type to aggregate independently of driving factors. This neuropathological signature can be used to assess the pathogenicity of UBQLN2 gene variants and to understand the mechanisms of UBQLN2-linked disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisFrontotemporal DementiaAutophagy-Related ProteinsHippocampusAdaptor Proteins, Signal TransducingHumansMaleMiddle AgedFemaleAgedDNA-Binding ProteinsAdultC9orf72 ProteinCell Cycle Proteins

Stichwörter der Autor:innen

UBQLN2amyotrophic lateral sclerosis (ALS)frontotemporal dementia (FTD)hippocampusneuropathologyubiquilin 2

Substanzen

UBQLN2 protein, humanAutophagy-Related ProteinsAdaptor Proteins, Signal TransducingDNA-Binding ProteinsC9orf72 ProteinCell Cycle Proteins

Autor:innen und Institutionen

  • School of Biological Sciences, University of Auckland, Auckland 1010, New Zealand.
  • Centre for Brain Research, University of Auckland, Auckland 1010, New Zealand.
  • Department of Anatomy and Medical Imaging, University of Auckland, Auckland 1010, New Zealand.
  • Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland 1010, New Zealand.
  • Department of Anatomical Pathology, LabPlus, Auckland City Hospital, Auckland 1010, New Zealand.
  • Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

ORCID-Profile: Helen C Murray, Molly E V Swanson, Clinton Turner, Emma L Scotter

Förderung

  • Amelia Pais-Rodriguez and Marcus Gerbich
  • Michael J Fox Foundation
  • Health Research Council Sir Charles Hercus Health Research Fellowship
  • Marsden FastStart and Rutherford Discovery Fellowship
  • Royal Society of New Zealand
  • Alzheimer's Disease Research and Education
  • Sir Thomas and Lady Duncan Trust
  • Coker Family Trust

Zitieren

APA

Thumbadoo, K. M., Dieriks, B. V., Murray, H. C., Swanson, M. E. V., Yoo, J. H., Mehrabi, N. F., Turner, C., Dragunow, M., Faull, R. L. M., Curtis, M. A., Siddique, T., Shaw, C. E., Newell, K. L., Henden, L., Williams, K. L., Nicholson, G. A., & Scotter, E. L. (2024). Hippocampal aggregation signatures of pathogenic UBQLN2 in amyotrophic lateral sclerosis and frontotemporal dementia. Brain. https://doi.org/10.1093/brain/awae140

Vancouver

Thumbadoo KM, Dieriks BV, Murray HC, Swanson MEV, Yoo JH, Mehrabi NF, et al. Hippocampal aggregation signatures of pathogenic UBQLN2 in amyotrophic lateral sclerosis and frontotemporal dementia. Brain. 2024. doi:10.1093/brain/awae140

BibTeX
@article{Thumbadoo2024,
  author = {Thumbadoo, Kyrah M and Dieriks, Birger V and Murray, Helen C and Swanson, Molly E V and Yoo, Ji Hun and Mehrabi, Nasim F and Turner, Clinton and Dragunow, Michael and Faull, Richard L M and Curtis, Maurice A and Siddique, Teepu and Shaw, Christopher E and Newell, Kathy L and Henden, Lyndal and Williams, Kelly L and Nicholson, Garth A and Scotter, Emma L},
  title = {Hippocampal aggregation signatures of pathogenic UBQLN2 in amyotrophic lateral sclerosis and frontotemporal dementia},
  journal = {Brain},
  year = {2024},
  doi = {10.1093/brain/awae140}
}
Kostenlos starten →